National Association of Testing Authorities, Australia
Scope of Accreditation
PathWest Laboratory Medicine WA
Site
QE II Medical Centre
Accreditation No.
2392
Site No.
2385
Date of Accreditation
30 May 1988
Contact
Ms Milana Ranieri P: +61 (08) 64571937
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Autoimmunity and Immunopathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Fresh tissue | Detection of antigenic targets - Various |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Serum | C1 esterase inhibitor |
| C1 esterase inhibitor functional | ||
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood | CD40 ligand; Stat1 |
| B-cell; Natural killer (NK) cells; T-cells | ||
| CD119; CD11a; CD11b; CD11c; CD127; CD14; CD16; CD18; CD19; CD21; CD25; CD27; CD3; CD38; CD4; CD45; CD45RA; CD56; CD62L; CD8; HLA-DR antigen; Immunoglobulin D (IgD); Immunoglobulin M (IgM); Natural killer (NK) cells; T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd) | ||
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Cerebrospinal fluid (CSF); Serum | Anti-CV2; Anti-Hu; Anti-Ma antibodies; Anti-Ri; Anti-Yo (anti-PCA1); Anti-amphiphysin; Anti-neuronal antibodies |
| Anti-Purkinje cell antibodies (PCA2); Anti-adrenal cortex antibodies; Anti-ovarian antibodies (AOA); Anti-steroid cell antibodies | ||
| Anti-N-methyl-D-aspartate receptor antibodies (NMDA); Anti-voltage gated potassium channel complex antibodies (VGKC) | ||
| Anti-AMPA-1; Anti-AMPA-2; Anti-gamma aminobutyric acid (GABA) B receptor antibodies | ||
| Serum | Anti-glomerular basement membrane antibodies (anti-GBM) | |
| Anti-neutrophil cytoplasmic antibodies (ANCA) | ||
| Anti-aquaporin 4 antibodies (AQP4); Anti-cardiac antibodies; Anti-striated muscle antibodies | ||
| Anti-extractable nuclear antigen antibodies (ENA) | ||
| Anti-double stranded DNA antibodies (dsDNA) | ||
| Anti-GD1a; Anti-GD1b; Anti-GD2; Anti-GD3; Anti-GM1; Anti-GM2; Anti-GM3; Anti-GM4; Anti-GQ1b; Anti-GT1a; Anti-GT1b; Anti-ganglioside antibodies | ||
| Anti-islet tyrosine phosphatase2 (IA2) antibodies | ||
| Anti-myelin associated glycoprotein antibodies (MAG) | ||
| Anti-RNA polymerase III antibodies (ARA, RNAP); Anti-cyclic citrullinated peptide antibodies (CCP); Anti-intrinsic factor antibodies (IF) | ||
| Anti-skin antibodies | ||
| Anti-HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) | ||
| Anti-cytosolic 5´-nucleotidase 1A (Anti-cN1A) | ||
| Anti-Jo-1 antibodies; Anti-La antibodies; Anti-Ro-52 antibodies; Anti-Ro-60 antibodies; Anti-Scl-70 antibodies; Anti-Smith antibodies (Sm); Anti-U1 ribonucleoprotein antibodies (U1 RNP); Anti-centromere protein B antibodies (Cenp-B); Anti-extractable nuclear antigen antibodies (ENA); Anti-histone antibodies (AHA); Anti-proliferating cell nuclear antigen (PCNA); Anti-ribosomal P protein antibodies | ||
| Anti-Saccharomyces cerevisiae antibodies (ASCA) | ||
| Anti-zinc transporter protein 8 antibodies (ZNT8) | ||
| Anti-phospholipase A2 receptor antibodies (PLA2R) | ||
| Anti-β2-glycoprotein-I antibodies | ||
| Anti-voltage gated calcium channel antibodies (VGCC) | ||
| Anti-glutamic acid decarboxylase antibodies (GAD) | ||
| Anti-EJ antibodies; Anti-Jo-1 antibodies; Anti-Ku antibodies; Anti-Mi-2 antibodies; Anti-NXP2 antibodies; Anti-OJ antibodies; Anti-PL-12 antibodies; Anti-PL-7 antibodies; Anti-Pm/Scl-100 antibodies; Anti-Pm/Scl-75 antibodies; Anti-Ro-52 antibodies; Anti-SAE1 antibodies; Anti-melanoma differentiation associated gene 5 antibodies (MDA5); Anti-myositis antibodies; Anti-signal recognition particle antibodies (SRP); Anti-transcription intermediary factor antibodies (TIF1) | ||
| Anti-acetylcholine receptor antibodies (AChR) | ||
| Anti-cardiolipin antibodies (ACA); Anti-deamidated gliadin antibodies; Anti-tissue transglutaminase antibodies (tTG) | ||
| Anti-liver cytosol antibodies (LC-1); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-soluble liver antigen antibodies (SLA); Anti-soluble liver antigen/liver-pancreas antibodies (SLA/LP) | ||
| Anti-glomerular basement membrane antibodies (anti-GBM); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3) | ||
| Anti-nuclear antibodies (ANA) | ||
| Anti-muscle specific kinase antibodies (MuSK) | ||
| Anti-gastric parietal cell antibodies (GPC/PCA); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-ribosomal P protein antibodies; Anti-smooth muscle antibodies (SMA) | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential component testing [purified native and/or recombinant allergens]) | Serum | Api m1 phospholipase A2 - Honey bee; Ara h2 - Peanut; Galactose-α-1,3-galactose thyroglobulin - Bovine; MUXF3 CCD; Ovomucoid - Egg; Pol d5 - European paper wasp; Tropomyosin - Shrimp; Ves v5 - Common wasp; α-Lactalbumin - Milk; β-Lactoglobulin - Milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Tetanus toxoid; Amoxicilloyl group; Ampicilloyl group; Chlorhexidine; Gelatin - Bovine; Insulin - Human; Morphine; Penicilloyl G; Penicilloyl V; Pholcodine; Rocuronium bromide; Suxamethonium (succinylcholine) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Budgerigar feathers; Canary bird feathers; Cat dander; Chicken feathers; Cow dander; Dog dander; Duck feathers; Ferret epithelium; Finch feathers; Goose feathers; Guinea pig epithelium; Hamster epithelium; Horse dander; Mouse epithelium; Mouse serum proteins; Mouse urine proteins; Parakeet feathers; Parrot feathers; Rabbit epithelium; Rat epithelium; Rat serum proteins; Rat urine proteins; Sheep epithelium; Turkey feathers |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [additives] allergens) | Serum | Tragacanth (E413) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg; Egg white; Egg yolk; Turkey meat |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Lobster; Octopus; Oyster; Salmon; Scallop; Shrimp; Squid; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Apple; Apricot; Aubergine (eggplant); Avocado; Banana; Beetroot; Blueberry; Broccoli; Carrot; Cauliflower; Celery; Fig; Garlic; Grape; Guava; Kiwi; Lemon citrus; Lime citrus; Mango; Melon; Olive - Black, fresh; Onion; Orange citrus; Peach; Pear; Pineapple; Potato; Strawberry; Tomato; Watermelon |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Mutton; Pork |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Casein; Cheese - Cheddar type; Goat milk; Milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Cacao; Coffee; Honey; Mushroom; Omega-5-gliadin; Yeasts |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Buck wheat; Cashew nut; Chick pea; Coconut; Gluten; Green bean; Hazelnut; Lentil; Lupin seed; Macadamia nut; Maize; Oat; Pea; Peanut; Pecan nut; Pinenut; Pistachio; Poppy seed; Pumpkin seed; Rapeseed; Rice; Rye; Sesame seed; Soy bean; Walnut; Wheat; White bean |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [spices] allergens) | Serum | Anise; Basil; Caraway; Cardamon; Chilli pepper; Cinnamon; Clove; Fennel seed; Ginger; Mace; Mint; Mustard; Nutmeg; Paprika (sweet pepper) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Bermuda grass; Cultivated wheat; Johnson grass; Kentucky blue; Rye grass; Sweet vernal grass; Timothy grass; Velvet grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | Fire ant; German cockroach; Horse fly Tabanus spp.; Mosquito |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Alternaria alternata; Anisakis; Ascaris spp. (roundworm); Aspergillus fumigatus; Candida albicans; Cladosporium herbarum; Echinococcus spp.; Malassezia spp.; Penicillium chrysogenum (formerly Penicillium notatum) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential miscellaneous allergens) | Serum | Seminal fluid |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Blomia tropicalis house dust mite; Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite; House dust - Hollister-Stier |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Latex; Sunflower seed |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Australian pine; Eucalyptus; Melaleuca; Olive; Silver birch; Wattle; White pine; Willow salix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Common wasp (yellow jacket) venom; European hornet venom; Honey bee venom; Paper wasp venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Common ragweed; Dandelion; Goldenrod; Lupin; Marguerite; Mugwort; Ox-eye daisy; Rapeseed |
| Immunopathology - Investigation and/or assessment of neutrophils - Functional tests | Blood | Qualitative assessment of neutrophils for the presence of oxidative pathway defects |
| Immunopathology - Investigation of natural killer cell release from target cells | Blood | Natural killer (NK) cell cytotoxicity |
| Immunopathology - Quantitation of complement proteins | Serum | Alternative pathway haemolytic complement; Total haemolytic complement |
| Mannose binding lectin (MBL) levels | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Plasma; Serum | Characterisation of cryoglobulins; Cryofibrinogen |
| Cryofibrinogen; Cryoglobulins | ||
| Cryofibrinogen; Cryoglobulins | ||
| Serum | Tryptase | |
| Immunopathology - Quantitative investigation and/or assessment of neutrophils | Blood | Oxidative burst |
| Polymorphonuclear cells; Serum | Bacterial killing; Chemotaxis measurement; Opsonisation | |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Total immunoglobulin E |
| Immunopathology - Tests of cellular immunity - Lymphocyte function tests | Blood | Proliferation by antigens; Proliferation by mitogens |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Tetanus IgG antibody |
| Streptococcus pneumoniae IgG antibody | ||
| Streptococcus pneumoniae IgG antibody | ||
| Anti-Aspergillus IgG; Anti-avian IgG - Budgerigar; Anti-avian IgG - Pigeon |
Clinical Biochemistry
ISO 15189 (2012)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Plasma | Caffeine |
| Plasma; Serum | Ethanol; Paracetamol (acetaminophen) | |
| Urine | Paraquat | |
| Chemical pathology - Biochemical genetic services for the diagnosis of metabolic and enzymological disorders | Plasma; Serum | Transferrin isoforms |
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Plasma; Serum | Asparaginase |
| Gentamicin (cidomycin, septopal, genticyn, garamycin); Lithium; Methotrexate; Salicylate; Tobramycin; Valproate (valproic acid, epilim) | ||
| Carbamazepine; Digoxin; Phenobarbitone; Phenytoin (dilantin); Theophylline; Vancomycin | ||
| Chemical pathology - Detection and/or quantitation of tumour markers | Cerebrospinal fluid (CSF) | α-Fetoprotein (AFP) |
| Human chorionic gonadotropin (hCG) | ||
| Plasma; Serum | CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); Human chorionic gonadotropin (hCG); Prostate specific antigen (PSA); Prostate specific antigen (PSA) fractions and derived index; α-Fetoprotein (AFP) | |
| Thyroglobulin | ||
| Serum; Urine | β2-Microglobulin (B2M) | |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma; Serum | C-peptide; Cortisol; Follicle stimulating hormone (FSH); Insulin; Luteinising hormone (LH); Macroprolactin; Oestradiol; Parathyroid hormone (PTH); Progesterone; Prolactin; Testosterone |
| Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| 17α-Hydroxyprogesterone; Androstenedione; Dihydrotestosterone; Oestradiol; Testosterone | ||
| Procalcitonin | ||
| Adrenocorticotropic hormone (ACTH); Dehydroepiandrosterone sulfate (DHEAS); Growth hormone; Insulin-like growth factor-binding protein 3 (IGF-BP3); Sex hormone binding globulin (SHBG) | ||
| Urine | Cortisol - Free | |
| Cortisol - Free | ||
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Blood; Plasma; Serum | Fructosamine; Glycated haemoglobin (HbA1c) | |
| Chemical pathology - Dynamic tests | Sweat | Sweat chloride; Sweat sodium |
| Chemical pathology - Further investigation of cardiac function | Plasma; Serum | Troponin I |
| Troponin I | ||
| B-type natriuretic peptide (BNP) | ||
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | HDL - Quantitation; LDL - Quantitation |
| Chemical pathology - Further investigation of renal and/or hepatic function | Plasma; Serum | Bile acids - Quantitative |
| Serum | Alkaline phosphatase (ALP) isoenzymes | |
| Caeruloplasmin | ||
| Haptoglobins; α1-Antitrypsin | ||
| Hyaluronic acid | ||
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Cerebrospinal fluid (CSF) | Bilirubin; Xanthochromia |
| Plasma | Plasma free haemoglobin | |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood; Plasma | Thiopurine methyltransferase (TPMT) |
| Cholinesterase | ||
| Cerebrospinal fluid (CSF) | Glucose; Protein - Total | |
| Cerebrospinal fluid (CSF); Pleural fluid | Adenosine deaminase | |
| Plasma; Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Cystatin C; Glucose; Lactate; Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | |
| Carbohydrate deficient transferrin | ||
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Bicarbonate; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Creatinine; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urea; γ-Glutamyltransferase | ||
| Albumin; Carbohydrate deficient transferrin | ||
| Plasma; Serum; Urine | Osmolality | |
| Serum | C1 esterase inhibitor; β-Trace protein (β-TP) | |
| Angiotensin converting enzyme (ACE); α2-Macroglobulin | ||
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Ammonia; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Creatinine; Glucose; Lactate dehydrogenase (LDH); Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urea; γ-Glutamyltransferase | ||
| Urine | Ketones | |
| Chloride | ||
| Albumin; Calcium - Total; Chloride; Creatinine; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | ||
| pH | ||
| Chemical pathology - Investigation for foetal lung maturity and/or foetal abnormalities | Amniotic fluid | α-Fetoprotein (AFP) |
| Chemical pathology - Investigation for folate deficiency | Blood; Plasma; Serum | Folate |
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C14 |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Serum | Free β-human chorionic gonadotropin (free β-hCG); Pregnancy associated plasma protein A (PAPP-A); α-Fetoprotein (AFP) |
| Chemical pathology - Investigation of porphyria | Blood; Plasma cells; Urine | Porphobilinogen (PBG); Porphyrins - Total |
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin |
| Iron; Transferrin | ||
| Iron; Transferrin | ||
| Chemical pathology - Newborn screening services for the diagnosis of inborn errors of metabolism | Dried blood spots | 11-Deoxycortisol; 17α-Hydroxyprogesterone; 21-Deoxycortisol; Androstenedione; Cortisol |
| Galactose metabolites | ||
| 17α-Hydroxyprogesterone; Immunoreactive trypsinogen; Thyroid stimulating hormone (TSH) | ||
| Acylcarnitine profile; Amino acids; Carnitines | ||
| Gal-1-p-uridyl transferase | ||
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Blood; Cerebrospinal fluid (CSF); Plasma; Serum; Urine | Acylcarnitine lactate; Amino acids; Aspartylglucosamine; Bile alcohols; Carnitines; Creatine; Free fatty acids - Total; Glycosaminoglycans (MPS); Guanidinoacetate; Lactate; Organic acids; Piperideine-6-carboxylate; Purine and pyrimidine metabolites; Pyruvate; n-Acetylneuraminic acid (sialic acid, NANA) |
| Cerebrospinal fluid (CSF); Plasma; Serum; Urine | Amino acids | |
| Plasma; Serum | β-Hydroxybutyrate | |
| Chemical pathology - Quantitation of vitamins | Blood; Plasma; Serum | 25-Hydroxyvitamin D; Cobalamin (vitamin B12); Holotranscobalamin (active vitamin B12) |
| Plasma; Serum | Carotenoids; Retinol (vitamin A); Tocopherol (vitamin E) | |
| Ascorbic acid (vitamin C) | ||
| Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Chemical pathology - Trace element analysis | Blood | Arsenic; Cadmium; Chromium; Cobalt; Iodine; Lead; Manganese; Mercury; Selenium |
| Liver | Copper; Iron | |
| Plasma | Aluminium; Chromium; Manganese; Selenium; Zinc | |
| Plasma; Serum | Copper | |
| Urine | Arsenic; Arsenic speciation; Cadmium; Chromium; Cobalt; Copper; Iodine; Lead; Manganese; Mercury; Nickel; Vanadium | |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma; Serum | Anti-thyroid peroxidase antibodies (TPO) |
| Anti-thyroglobulin antibodies (Tg) | ||
| Serum | Rheumatoid factor | |
| Immunopathology - Quantitation of complement proteins | Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Cerebrospinal fluid (CSF); Serum | Oligoclonal bands |
| Serum | Detection and quantitation of free kappa and free lambda light chains | |
| Albumin; Detection and quantitation of free kappa and free lambda light chains; α1-Globulin; α2-Globulin; β-Globulin; γ-Globulin | ||
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Streptococcal anti-DNAse B (anti-streptodornase) antibody; Anti-streptolysin O (ASOT) |
Clinical Pharmacology and Toxicology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Serum | Methadone |
| Methanol | ||
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | 6-Mercaptopurine; 6-Thioguanine; Cyclosporin; Everolimus; Sirolimus; Tacrolimus |
| Plasma; Serum | Linezolid | |
| Serum | Teicoplanin; Thiopentone | |
| 5-Flucytosine; 9-Hydroxyrisperidone; Amiodarone; Busulfan; Clozapine; Cotinine; Desmethyl venlafaxine; Ganciclovir; Hydroxychloroquine; Hydroxyperhexiline (OH-perhexiline); Infliximab; Itraconazole; Lamotrigine; Levetiracetam; Mycophenolate; Norclozapine; Olanzapine; Perhexiline; Posaconazole; Quetiapine; Risperidone; Venlafaxine; Voriconazole; Warfarin | ||
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Plasma; Serum | Immunoglobulin G (IgG) subclasses; Total immunoglobulin G |
| Serum | Total immunoglobulin D |
ISO 15189 (2022)
Legal
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, section 2 Specimen collection, storage, handling and dispatch | Urine | Colour; Creatinine; Temperature; pH |
| Medico legal drug testing AS/NZS 4308:2008, section 3 General laboratory requirements | Urine | General laboratory requirements as described in AS/NZS 4308 |
| Medico legal drug testing AS/NZS 4308:2008, section 4 Laboratory screening procedures | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, section 5 Laboratory confirmatory procedures | Urine | 11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; Benzoylecgonine (ecgonine benzoate) |
| 6-Acetylmorphine; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Nordiazepam; Oxazepam; Temazepam; α-Hydroxyalprazolam | ||
| Amphetamines; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Phentermine; Pseudoephedrine (PSE) | ||
| Codeine; Morphine |
Diagnostic Genomics
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in situ hybridisation techniques | Amniotic fluid; Blood; Chorionic villus tissue; Lymph nodes; Other tissues - Malignant; Other tissues - Non-malignant; Paraffin embedded tissue; Products of conception (POC); Tumour imprints | Chromosomal rearrangement; Constitutional genetic abnormalities; Cytogenetic analysis and reporting; Pathogenic copy number changes; Variations of unknown significance |
| Chromosomal rearrangement; Constitutional genetic abnormalities; Cytogenetic analysis and reporting; Pathogenic copy number changes; Variations of unknown significance | ||
| Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities | Amniotic fluid; Blood; Chorionic villus tissue; Other body fluids; Other tissues - Malignant; Other tissues - Non-malignant; Products of conception (POC); Tissues | Cytogenetic analysis and reporting |
| Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities | Amniotic fluid; Blood; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant; Products of conception (POC); Tissues | Cytogenetic analysis and reporting; Pathogenic copy number changes; Uniparental or biparental chromosome inheritance |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Amniotic fluid; Blood; Buccal swabs; Chorionic villus; Dried blood spots; Extracted DNA; Purified DNA | Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Fragile X messenger ribonucleoprotein 1 (FMR1) related disorders; Fragile X syndrome (FRAXA); Friedreich's ataxia (FRDA, FA); Huntington's disease; Kennedy's disease (spinal and bulbar muscular atrophy); Myotonic dystrophy; Nudix hydrolase 15 gene (NUDT15); Spinocerebellar ataxia |
| Molecular genetics - DNA extraction | Amniotic fluid; Blood; Body fluids; Buccal swabs; Buffy coat; Cerebrospinal fluid (CSF); Chorionic villus tissue; Cultured cells; Fibroblast cell pellets; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue; Muscle; Products of conception (POC); Saliva; Skin biopsy; Tissue biopsy; Tissues; Urine | Viable DNA for sequencing and other molecular assays |
| Blood | Viable DNA for sequencing and other molecular assays | |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes | Amniotic fluid; Blood; Bone marrow; Buccal swabs; Chorionic villus; Cultured cell pellets; Dried blood spots; Extracted DNA; Formalin-fixed paraffin-embedded (FFPE) tissues; Frozen tissue; Muscle; Products of conception (POC); Skin fibroblasts; Tissues; Urine | Blood borne tumours; Congenital adrenal hyperplasia; Cystic fibrosis; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Facioscapulohumeral muscular dystrophy; Familial motor neurone diseases; Fragile X messenger ribonucleoprotein 1 (FMR1) related disorders; Fragile X syndrome (FRAXA); Friedreich's ataxia (FRDA, FA); Galactosemia; Haemoglobin subunit alpha 1 (HBA1); Haemoglobin subunit alpha 2 (HBA2); Haemoglobin subunit beta (HBB); Hereditary breast and ovarian cancer syndrome; Hereditary colorectal cancer; Hereditary haemochromatosis; Hereditary non-syndromic deafness; Hereditary pancreatitis; Huntington's disease; Incontinentia pigmenti; Inherited cancer syndromes; Inherited cardiac disorders - LQT, Brugada syndrome, DCM, HCM, ARVC, CPVT, aortopathy; Inherited disorders; Kennedy's disease (spinal and bulbar muscular atrophy); Li-Fraumeni syndrome; Long chain 3-hydroxyacyl-coenzyme A dehydrogenase (LHCAD) deficiency; Lynch syndrome; Mendelian disorders; Myotonic dystrophy; Neuromuscular disorders; Oculopharyngeal muscular dystrophy; Rare undiagnosed disease; Skeletal dysplasia; Spinal muscular atrophy; Spinocerebellar ataxia; Thiopurine methyltransferase (TPMT) genotyping; Variants in the nuclear genome; Y chromosome microdeletion; α-Thalassaemia; β-Thalassaemia |
| Extracted DNA | Spinal muscular atrophy; Survival of motor neuron 1 (SMN1) | |
| Cystic fibrosis | ||
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Whole genome sequencing studies for inherited (germline) DNA/RNA changes | Extracted DNA | Inherited disorders |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Amniotic fluid; Blood; Bone marrow; Buccal swabs; Chorionic villus; Cultured cell pellets; Dried blood spots; Extracted DNA; Muscle; Products of conception (POC); Skin fibroblasts; Tissue culture cells; Tissues; Urine | Angelman syndrome; Beckwith-Wiedemann syndrome; Charcot-Marie-Tooth neuropathy; Congenital adrenal hyperplasia; Cystic fibrosis; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); DiGeorge syndrome; Duchenne-Becker muscular dystrophy; Facioscapulohumeral muscular dystrophy; Familial motor neurone disease - Amyotrophic lateral sclerosis (ALS); Fragile X; Fragile X messenger ribonucleoprotein 1 (FMR1) related disorders; Fragile X syndrome (FRAXA); Friedreich's ataxia (FRDA, FA); Galactosemia; Guanine nucleotide binding protein (GNAS) related disorders; Hemangioblastoma; Hereditary haemochromatosis; Hereditary neuropathy with liability to pressure palsies; Hereditary pancreatitis; Huntington's disease; Incontinentia pigmenti; Kennedy's disease (spinal and bulbar muscular atrophy); Long chain 3-hydroxyacyl-coenzyme A dehydrogenase (LHCAD) deficiency; Mendelian disorders; Mitochondrial disorders; Myotonic dystrophy; Oculopharyngeal muscular dystrophy; Prader-Willi syndrome; Rare undiagnosed disease; Russell-Silver syndrome (Silver-Russell syndrome); Skeletal dysplasia; Spinal muscular atrophy; Spinocerebellar ataxia; Thiopurine methyltransferase (TPMT) genotyping; Uniparental disomy 14,7; Variant haemoglobin; Variants in the nuclear genome; Y chromosome AZF deletions; α-Thalassaemia; β-Thalassaemia |
| Blood | Haemochromatosis; Thiopurine methyltransferase (TPMT); α1-Antitrypsin | |
| Blood; Muscle | Mitochondrial disorders; Progressive external ophthalmoplegia | |
| Blood; Saliva | Cystic fibrosis | |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood | Heterogeneous Inherited disorders |
| Inherited disorders; Neuromuscular disorders | ||
| Androgen receptor; Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES); Congenital adrenal hyperplasia; Gilberts disease; Incontinentia pigmenti; α-Thalassaemia; β-Thalassaemia | ||
| Blood; Tissues | Cowden syndrome (multiple hamartoma syndrome); Familial adenomatous polyposis; Inherited cancer syndromes; Li-Fraumeni syndrome; Lynch syndrome; Multiple endocrine neoplasia; Neurofibromatosis; Peutz-Jeghers syndrome; Retinoblastoma; Tuberous sclerosis; Von Hippel Lindau disease | |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Whole exome sequencing studies for inherited (germline) DNA/RNA changes | Blood | Copy number variation (CNV); Inherited cancer syndromes; Inherited disorders; Inherited solid tumours; Neuromuscular disorders |
| Molecular genetics - Non-invasive prenatal (genetic) screening | Extracted DNA | Rhesus D Antigen exons 5 and 7 |
| Molecular genetics - Predictive genetic testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood | Huntington's disease; Inherited cancer syndromes; Myotonic dystrophy |
| Molecular genetics - Prenatal genetic testing (excluding non-invasive prenatal [genetic] screening) | Amniotic fluid; Chorionic villus | Trisomy 13, trisomy 18, trisomy 21; Trisomy X; Trisomy Y |
| Molecular genetics - Screening for an unknown mutation - Targeted genes | Blood | Facioscapulohumeral muscular dystrophy |
| Facioscapulohumeral muscular dystrophy | ||
| Dried blood spots | Severe combined immunodeficiency disease (SCID); Spinal muscular atrophy | |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences; FASTQ files; RNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
Division of Tissue Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical smear; Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Endometrial pipelle; Vaginal smears; Vault smears | Cytological examination; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Cerebrospinal fluid (CSF); Other body fluids; Sputum; Urine; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Anus smears; Nipple discharge | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix; Liquid based cytology specimens from vaginal vault | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities; Structured reporting |
| Anatomical pathology - Tissue pathology - Examination of biopsy material by electron microscopy | Fluids; Formalin-fixed tissue; Hair; Nasal brushings | Review and reporting of biopsy material to identify or exclude ultra-structural morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue; Smears; Tissue imprint | Intra-operative consultation and examination of biopsy material; Rapid onsite evaluation (ROSE) |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | Detection of antigenic targets - Various |
| Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities | Paraffin embedded tissue | Pathogenic copy number changes |
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis for post vasectomy and/or examination of cervical mucus | Semen | Presence of spermatozoa |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Cervical specimen; Liquid based cytology specimens; Vaginal vault specimens; Vault smears | Human papilloma virus (HPV) |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood; Bone marrow; Formalin-fixed paraffin-embedded (FFPE) tissues | KIT D816v mutation analysis; Rare undiagnosed disease |
| Blood; Fluids; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Haematolymphoid malignancies; Solid tumours | |
| Blood; Formalin-fixed paraffin-embedded (FFPE) tissues | EGFR mutation analysis | |
| Formalin-fixed paraffin-embedded (FFPE) tissues | DNA copy number | |
| MYD88 mutation analysis | ||
| RAS mutation analysis | ||
| Glioblastoma; MGMT promoter methylation analysis | ||
| Variants in the nuclear genomeAdd TERT Promoter variants and then remove Variants in the nuclear genome. | ||
| Lynch syndrome | ||
| EGFR T790m variant | ||
| Molecular genetics - DNA extraction | Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Viable DNA for sequencing and other molecular assays |
| Molecular genetics - DNA sequencing | Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Sequenced DNA utilising massively parallel sequencing technologies |
| Molecular genetics - Detection and characterisation of cell free RNA (cfRNA)/cell free DNA (cfDNA)/cell free TNA (cfTNA)/circulating tumour DNA (ctDNA) in cancer screening and/or cancer genetic testing | Blood | Nucleic acid analysis for specific variants |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Haematolymphoid malignancies; Solid tumours |
| Molecular genetics - Heterozygous loci determinations | Blood; Fluids; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | Haematolymphoid malignancies; Solid tumours |
| Molecular genetics - RNA extraction | Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Viable RNA for molecular diagnostics; Viable RNA for sequencing |
| Molecular genetics - Screening for an unknown mutation - Targeted panels for non-inherited (somatic) DNA/RNA changes | Formalin-fixed paraffin-embedded (FFPE) tissues | Haematological malignancies; Solid tumours; Somatic mutation detection |
| Haematological malignancies; Solid tumours; Somatic mutation detection | ||
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
Forensic Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Tissue pathology - Coronial autopsy services | Body; Body parts | Autopsy service and reporting |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Mortuary facilities | Body; Body parts | Assessment - Level 3 mortuary |
Haematology/Immunohaematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material; Histological examination |
| Haematology - Diagnosis of thalassemia | Blood | Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation |
| Haematology - Examination of blood films by special staining | Blood | Malaria |
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Feto-maternal haemorrhage (FMH) estimation |
| Haematology - Full blood examination | Blood | Morphology |
| Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Mean platelet volume (MPV); Platelet count; Red blood cell distribution width (RDW); Red blood cell index or indices; Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | ASPtest; Adenosine diphosphate (ADPtest); TRAPtest |
| Viscoelastic haemostatic testing (VHT) | ||
| Platelet aggregation | ||
| Platelet function (PFA) | ||
| Plasma | Heparin induced thrombotic thrombocytopenia (HITT) | |
| Activated partial thromboplastin time (APTT); Anti-Xa - Apixaban; Anti-Xa - Dabigatran; Anti-Xa - Fondaparinux; Anti-Xa - Rivaroxaban; Anti-Xa activity - Clexane - Low molecular weight heparin; Anti-Xa activity - Fragmin - Low molecular weight heparin; Anti-Xa activity - Unfractionated heparin; Anti-thrombin III; D-dimer; Factor II; Factor IX; Factor V; Factor VII; Factor VIII; Factor VIII inhibitor; Factor X; Factor XI; Factor XII; Factor XIII; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Protein C and protein S; Thrombin time (TT); Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Factor XIII | ||
| Factor XIII | ||
| Collagen binding activity | ||
| Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Haemoglobin S (HbS) - Presence |
| Haematology - Investigation of haemolysis | Blood | Donath-Landsteiner antibody |
| Serum | Cold agglutinins | |
| Urine | Haemosiderin | |
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Immunohaematology - Blood group antibody detection | Blood | Duffy system; Kell system; M and N factors; Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Direct antiglobulin test (DAT, direct Coombs test) |
| Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies | ||
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Other blood group antibodies; Rh |
| Antibody elution | ||
| Red blood cell phenotyping | ||
| Immunohaematology - Investigation of blood transfusion reactions | Blood; Blood products; Plasma | Antibodies; Contamination - Microbiological; Direct antiglobulin test (DAT, direct Coombs test); Group checks of patient and donor |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Compliance with transport, storage and distribution requirements of blood, products and components |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Aspirates; Blood; Bone marrow; Cerebrospinal fluid (CSF); Fresh tissue; Serous fluid | CD10; CD103; CD117; CD11b; CD11c; CD123; CD13; CD138; CD14; CD15; CD157; CD16; CD19; CD1a; CD2; CD20; CD200; CD22; CD23; CD235a; CD25; CD3; CD30; CD303; CD304; CD33; CD34; CD36; CD38; CD4; CD43; CD45; CD5; CD56; CD57; CD61; CD64; CD7; CD71; CD79a; CD79b; CD8; CD81; CD9; HLA-DR antigen; Immunoglobulin D (IgD); Immunoglobulin M (IgM); Kappa light chains; Lambda light chains; Myeloperoxidase; T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT) |
| Blood | Eosin-5-maleimide; Paroxysmal nocturnal haemoglobinuria (PNH) surface markers | |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Plasma | Infectious mononucleosis |
Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Bacterial isolates | Bacteria; Pathogenic identification and antibiotic susceptibility |
| Pathogenic identification | ||
| Antibiotic susceptibility | ||
| Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Faeces; Fluids; General swabs; Sputum; Synovial fluid | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Faeces; Fluids; General swabs; Sputum; Synovial fluid; Urine | Bacteria; Pathogenic microorganisms | |
| Blood | Bacteria; Pathogenic microorganisms | |
| Faeces | Clostridioides difficile | |
| Urine | Legionella antigen; Streptococcus pneumoniae antigen | |
| Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Red blood cell morphology; Urinary sediment | ||
| Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | ||
| Bilirubin; Blood; Glucose; Leucocyte esterase; Nitrite; Proteins; Specific gravity; Urobilinogen; pH | ||
| Microbiology - Bacteriology - Public health investigation and/or monitoring of outbreaks of infection | Isolates | Detection and characterisation of bacteria (including identification and typing) |
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Environmental swabs | Bacterial organism identification - Acinetobacter; Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA) |
| Gastrointestinal endoscopes | Bacterial growth - Sterility | |
| Spore strips | Bacterial growth - Sterility | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Amniotic fluid; Cerebrospinal fluid (CSF); Dry swabs; Tissues | Treponema pallidum |
| Anal swab; Eye swabs; Genital swabs; Rectal swabs; Throat swabs; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Anal swab; Rectal swabs | Mycoplasma genitalium | |
| Bacterial isolates | Haemophilus influenzae typing | |
| Burkholderia pseudomallei | ||
| Staphylococcus aureus blaZ gene | ||
| Bacterial isolates; Blood; Cerebrospinal fluid (CSF); Fluids; Sterile site | Neisseria meningitidis | |
| Bacterial isolates; Fluids | Kingella kingae | |
| Blood | Staphylococcus aureus; Methicillin resistant Staphylococcus aureus (MRSA) | |
| Blood; Cerebrospinal fluid (CSF) | Streptococcus agalactiae (Streptococcus group B) | |
| Blood; Cerebrospinal fluid (CSF); Sterile site | Streptococcus pneumoniae | |
| Blood; Cerebrospinal fluid (CSF); Tissues | Coxiella burnetti | |
| Tropheryma whipellii | ||
| Rickettsia genus-specific | ||
| Blood; Fluids; Sterile site; Tissues | Streptococcus pyogenes | |
| Blood; Tissues | Orientia tsutsugamushi (scrub typhus) | |
| Bartonella henselae | ||
| Cerebrospinal fluid (CSF) | Escherichia coli K1; Haemophilus influenzae; Listeria monocytogenes; Neisseria meningitidis; Streptococcus agalactiae (Streptococcus group B); Streptococcus pneumoniae | |
| Cerebrospinal fluid (CSF); Respiratory specimens | Chlamydophila psittaci | |
| Cerebrospinal fluid (CSF); Respiratory specimens; Tissues | Chlamydophila pneumoniae; Mycoplasma pneumoniae | |
| Cervical swabs; Urine; Vaginal swabs | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Eye swabs; Genital swabs; Rectal swabs; Throat swabs; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Faeces | Clostridioides difficile; Escherichia coli - Enteroinvasive (EIEC); Escherichia coli STEC stx1/stx2; Plesiomonas shigelloides; Salmonella spp.; Shigella spp.; Vibrio cholerae; Vibrio parahaemolyticus; Vibrio vulnificus; Yersinia enterocolitica | |
| Fluids; Genital swabs; Respiratory specimens; Tissues; Urine | Mycoplasma hominis | |
| Genital swabs; Meatal swabs; Urine | Mycoplasma genitalium; Trichomonas vaginalis | |
| Genital swabs; Rectal swabs; Respiratory specimens; Urine | Neisseria gonorrhoeae; Antibiotic resistance gene detection | |
| Genital swabs; Rectal swabs; Throat swabs; Urine | Azithromycin resistant Mycoplasma genitalium | |
| Genital swabs; Tissues | Klebsiella granulomatis | |
| Genital swabs; Urine | Ureaplasma parvum; Ureaplasma urealyticum | |
| Rectal swabs | Chlamydia trachomatis serovars L1, L2, L2a or L3 (LGV) | |
| Respiratory specimens | Bordetella pertussis | |
| Legionella longbeachae; Legionella pneumophila | ||
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (fungi) | Bronchoalveolar lavage; Respiratory specimens | Pneumocystis jirovecii |
| Cerebrospinal fluid (CSF) | Cryptococcus gattii; Cryptococcus neoformans | |
| Isolates | Panfungal - Internal transcribed spacer (ITS) | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Bacterial isolates | Mycobacteria identification |
| Bacterial isolates; Cerebrospinal fluid (CSF); Respiratory specimens; Tissues | Mycobacterium tuberculosis complex | |
| Bacterial isolates; Sputum | Mycobacterium tuberculosis; Mycobacterium rifampicin resistance rpoB | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Amniotic fluid; Blood; Cerebrospinal fluid (CSF); Ocular fluid | Toxoplasma gondii |
| Blood | Plasmodium falciparum; Plasmodium knowlesi; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax | |
| Faeces | Cryptosporidium hominis; Cryptosporidium parvum; Cyclospora cayetanensis; Entamoeba histolytica; Giardia intestinalis | |
| Genital swabs; Urine | Trichomonas vaginalis | |
| Isolates | Naegleria fowleri | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Amniotic fluid; Blood; Cerebrospinal fluid (CSF); Dried blood spots; Dry swabs; Faeces; Plasma; Respiratory specimens; Serum; Tissues; Urine | Cytomegalovirus (CMV) |
| Amniotic fluid; Blood; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Respiratory specimens; Skin swabs; Sterile site; Tissues; Urine | Enterovirus | |
| Amniotic fluid; Blood; Respiratory specimens; Tissues; Urine | Rubella virus | |
| Amniotic fluid; Blood; Serum; Tissues | Human herpes virus (HHV); Parvovirus B19 | |
| Blood | Human immunodeficiency virus type 1 (HIV-1) RNA | |
| Human T-lymphotropic virus type I (HTLV-I) | ||
| Blood; Cerebrospinal fluid (CSF); Plasma; Serum | Human herpes virus type 6 (HHV6) | |
| Human herpes virus type 7 (HHV7) | ||
| Dengue virus 1; Dengue virus 2; Dengue virus 3; Dengue virus 4 | ||
| Blood; Cerebrospinal fluid (CSF); Tissues | Epstein-Barr virus | |
| Blood; Cerebrospinal fluid (CSF); Tissues; Urine | John Cunningham virus (JC) | |
| Blood; Faeces; Plasma; Serum | Hepatitis A virus (HAV) | |
| Blood; Plasma; Serum | Human herpes virus type 8 (HHV8) | |
| Blood; Respiratory specimens; Urine | Measles virus | |
| Buccal swabs; Mouth swabs; Throat swabs; Urine | Mumps virus | |
| Cerebrospinal fluid (CSF) | Human parechovirus | |
| Cytomegalovirus (CMV); Enterovirus; Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Human herpes virus type 6 (HHV6); Human parechovirus; Varicella zoster virus (VZV) | ||
| Cerebrospinal fluid (CSF); Dry swabs | Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
| Cerebrospinal fluid (CSF); Eye swabs; Faeces; Respiratory specimens; Tissues; Urine | Adenovirus | |
| Cerebrospinal fluid (CSF); Respiratory specimens; Skin swabs | Enterovirus 71 | |
| Cerebrospinal fluid (CSF); Urine | BK virus | |
| Dry swabs | Molluscum contagiosum virus; Parapox virus | |
| Faeces | Adenovirus F40; Adenovirus F41; Astrovirus; Norovirus G1; Norovirus G2; Rotavirus A; Sapovirus I; Sapovirus II; Sapovirus IV; Sapovirus V | |
| Adenovirus F40; Adenovirus F41; Norovirus; Rotavirus | ||
| Genital swabs; Liquid based cytology specimens; Rectal swabs; Tissues | Human papilloma virus (HPV) | |
| Nasal swabs; Nasopharyngeal and throat swab; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasal swabs; Nasopharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasopharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | |
| Paraffin embedded tissue | Human papilloma virus (HPV) | |
| Respiratory specimens | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Influenza A virus; Influenza B virus | ||
| Influenza A virus H1; Influenza A virus H3 | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Monkeypox virus | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Human metapneumovirus; Influenza A virus; Influenza A virus H1/09; Influenza A virus H3; Influenza B virus; Parainfluenza virus type 1/2/3; Respiratory syncytial virus (RSV) A/B | ||
| Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | ||
| Respiratory specimens; Tissues | Rhinovirus | |
| Respiratory swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | |
| Microbiology - Molecular biology - Microbial genotyping | Blood; Serum | Hepatitis B virus (HBV) genotyping; Drug resistance and pre-core and basal core mutations |
| Microbiology - Molecular biology - Surveillance programme for the detection of microbial nucleic acids (viruses) in accordance with Commonwealth and/or State Health protocols | Saliva | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Blood; Cerebrospinal fluid (CSF); Faeces; Other body fluids; Respiratory specimens; Tissues; Urine | Mycobacteria antibiotic susceptibility |
| Other pathogenic bacteria to genus level or species level | ||
| Mycobacteria identification | ||
| Blood; Other body fluids | Mycobacteria detection | |
| Cerebrospinal fluid (CSF); Faeces; Respiratory specimens; Tissues; Urine | Mycobacteria detection | |
| Isolates | Other pathogenic bacteria to genus level or species level | |
| Mycobacteria antibiotic susceptibility | ||
| Other pathogenic bacteria to genus level or species level | ||
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Cerebrospinal fluid (CSF); Isolates | Fungi identification; Yeasts identification |
| Cerebrospinal fluid (CSF); Serum | Cryptococcus antigen | |
| Fluids; General swabs; Respiratory specimens; Respiratory swabs; Skin scrapings; Tissues | Fungi identification; Yeasts identification | |
| Fluids; Respiratory swabs; Skin scrapings; Tissues | Fungi identification; Yeasts identification | |
| Isolates | Yeast susceptibility | |
| Fungi identification; Yeasts identification | ||
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cryptosporidia; Microsporidia; Cysts; Ova; Parasites |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Plasma; Serum | Epstein-Barr virus IgM antibody |
| Dengue virus IgG antibody; Dengue virus IgM antibody; Dengue virus NS1 antigen | ||
| Cerebrospinal fluid (CSF) | Syphilis Treponema pallidum antibody | |
| Plasma; Serum | Echinococcus granulosus IgG antibody | |
| Barmah forest virus IgM antibody; Japanese encephalitis virus (JEV); Kunjin virus; Measles IgM antibody; Mumps virus IgM antibody; Murray Valley encephalitis virus; Ross River virus IgM antibody; Zika virus IgM antibody | ||
| Human immunodeficiency virus (HIV) p24 antigen | ||
| Hepatitis E virus (HEV) IgG | ||
| Dengue virus NS1 antigen | ||
| Syphilis Treponema pallidum antibody | ||
| Cytomegalovirus (CMV) IgG avidity; Hepatitis B virus surface antigen (HBs Ag); Hepatitis B virus surface antigen (HBs Ag) neutralisation; Rubella IgM antibody; Toxoplasma spp. IgM antibody; Lyme IgG antibody; Lyme IgM antibody | ||
| Coxiella burnetii (Q-fever) IgG phase 1 antibody; Coxiella burnetii (Q-fever) IgG phase 2 antibody; Coxiella burnetii (Q-fever) IgM phase 1 antibody; Coxiella burnetii (Q-fever) IgM phase 2 antibody | ||
| Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies | ||
| Chikungunya virus IgM antibody; Japanese encephalitis virus (JEV) IgG antibody; Japanese encephalitis virus (JEV) IgM antibody; Legionella longbeachae antibody; Legionella pneumophila total antibody; Yellow fever virus IgM antibody | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | ||
| Echinococcus spp. IgG antibody | ||
| Entamoeba histolytica IgG antibody | ||
| Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis B virus surface antigen (HBs Ag) - Quantitative; Hepatitis C virus antibody (anti-HCV); Human T-lymphotropic virus type I/II (HTLV-I/II) antibody; Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies; Human immunodeficiency virus type 1/2 (HIV-1/2) antigen; Rubella IgG antibody; Syphilis Treponema pallidum antibody; Toxoplasma gondii IgG antibody; Toxoplasma gondii IgM antibody | ||
| Ross River virus IgG antibody | ||
| Chlamydial pneumoniae IgG antibody | ||
| Bordetella pertussis IgG; Epstein-Barr virus nuclear antigen IgG antibody; Epstein-Barr virus viral capsid antigen IgG antibody; Epstein-Barr virus viral capsid antigen IgM antibody; Hepatitis D virus antibody (anti-HDV); Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Measles IgG antibody; Measles IgM antibody; Mumps virus IgG antibody; Mumps virus IgM antibody; Mycoplasma pneumoniae IgG antibody; Mycoplasma pneumoniae IgM antibody; Parvovirus B19 IgG antibody; Parvovirus B19 IgM antibody; Varicella zoster virus (VZV) IgG antibody; Varicella zoster virus IgM antibody | ||
| Schistosoma mansoni IgG antibody | ||
| Human herpes virus type 6 (HHV6) IgG antibody; Human herpes virus type 6 (HHV6) IgM antibody | ||
| Hepatitis C virus antibody (anti-HCV) - IgG | ||
| Ross River virus IgM antibody | ||
| Barmah forest virus IgM antibody | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid IgG antibody; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG antibody | ||
| Syphilis Treponema pallidum antibody | ||
| Orientia tsutsugamushi (scrub typhus); Rickettsia typhi; Spotted fever group; Typhus group | ||
| Brucella IgM antibody | ||
| Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis B virus surface antigen (HBs Ag) - Confirmatory; Hepatitis B virus surface antigen (HBs Ag) - Quantitative; Hepatitis C virus antibody (anti-HCV); Human T-lymphotropic virus type I/II (HTLV-I/II); Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies; Human immunodeficiency virus type 1/2 (HIV-1/2) antigen; Rubella IgG antibody; Syphilis Treponema pallidum antibody; Toxoplasma gondii IgG antibody; Toxoplasma gondii IgM antibody | ||
| Brucella IgG antibody | ||
| Barmah forest virus IgG antibody | ||
| Syphilis Treponema pallidum IgM antibody | ||
| Serum | Strongyloides IgG antibody | |
| Taenia solium IgG antibody | ||
| Dengue virus IgM antibody | ||
| Bartonella henselae IgG antibody | ||
| Helicobacter pylori IgG antibody | ||
| Burkholderia pseudomallei | ||
| Leptospira IgM antibody |
PCH Diabetes Clinic D
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
PCH Diabetes Clinic G
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
PCH Emergency Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
PCH Hybrid Biplane Theatre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
PCH Level 3 Shared Pathology Bay
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
PCH Theatre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
PCH Ward 3A (PICU)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
PCH Ward 3B (NICU)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Perth Children’s Hospital (PCH) limited AP & Mortuary
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Mortuary facilities | Body | Assessment - Level 2 mortuary |
| Anatomical pathology - Tissue pathology - Non-coronial autopsy services | Body parts | Autopsy service and reporting |
SCGH – Diabetic Clinic
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
SCGH – Emergency Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
SCGH – Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
SCGH – Post-Anaesthesia Care Unit (PACU)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
SCGH – Radiation Oncology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Creatinine |
SCGH – Radiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Creatinine |
SCGH Podiatry Clinic
ISO 15189 (2022)
Human Pathology
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
SCGH Pre-Admission Clinic
ISO 15189 (2022)
Human Pathology
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
SCGH-HITH
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | International normalised ratio (INR) |
SCGH-MRI
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Creatinine |
Stem Cell Transplant Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
26 Jan 2027
Last Activity Date
10 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cellsAutologous processing; Product received from AN 18796 SN 20921 | Haemopoietic progenitor cells | Enumeration of CD34+ cells |
| Processing; Storage (includes freezing/thawing) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2392
Site No.
2385
Print date
21 Apr 2025
END OF SCOPE